Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
NEGG Newegg Commerce Inc
PHX PHX Minerals Inc
IRT Independence Realty Trust Inc
RLAY Relay Therapeutics Inc
CVU CPI Aerostructures Inc
MA Mastercard Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Closing Price
$0.83
Day's Change
-0.0566 (-6.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.907
Day's Low
0.83
Volume
(Light)
Volume:
4,584,488

10-day average volume:
9,975,315
4,584,488

CURV, OLPX & BRDS Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate

11:01 am ET January 12, 2023 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / January 12, 2023 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Bronstein, Gewirtz and Grossman, LLC, Thursday, January 12, 2023, Press release picture

Torrid Holdings(NYSE:CURV)

Class Period: Torrid securities pursuant and/or traceable to the Company's initial public offering conducted in July 2021 (the "IPO")

Deadline: January 17, 2023

For more info: www.bgandg.com/curv

The Complaint alleges that Torrid's IPO's offering documents failed to disclose the following material facts: (1) in the first half of 2021, Torrid had experienced a temporary surge in demand as a result of changed consumer behaviors in response to the COVID-19 pandemic and government stimulus and that such ephemeral demand trends had dissipated and were not internally projected to continue following the IPO; (2) Torrid was suffering from severe supply chain disruptions caused by the emergence of the Delta variant of COVID-19, which had first emerged in May 2021; (3) Torrid was running materially below historical inventory levels as a result of supply chain disruptions; (4) as a result, Torrid did not have sufficient inventory to meet expected consumer demand for its fiscal third quarter of 2021; (5) as a result, late inventory arrival had materially impaired the Company from effectively matching consumer buying trends, creating an undisclosed risk of increased markdowns and promotional activities necessary to sell undesirable inventory; (6) Torrid's CFO planned to retire shortly after the IPO; and (7) as a result of the above, the Registration Statement's representations regarding Torrid's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the IPO, and were materially false and misleading and lacked a reasonable factual basis.

Olaplex Holdings, Inc. (NASDAQ:OLPX)

Class Period: Olaplexcommon stock pursuant and/or traceable to the Company's Offering Documents issued in connection with the initial public offering conducted on or around September 30, 2021 (the "IPO")

Deadline: January 17, 2023

For more info: www.bgandg.com/olpx

The Complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and was not prepared in accordance with the rules and regulations governing its preparation. Specifically, the Offering Documents made false and/or misleading statements and/or failed to disclose that: (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the Offering Documents; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

Bird Global, Inc. (NYSE:BRDS)

f/k/a Switchback II Corporation

Class Period: May 14, 2021 - November 14, 2022

Deadline: January 17, 2023

For more info: www.bgandg.com/brds

The Complaint alleges that the Defendants made statements that were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operational and financial results, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Bird was improperly recording Sharing Revenue for certain trips by its customers where collection was not probable; (2) as such, Bird overstated its Sharing Revenue for the relevant quarters and fiscal year during the Class Period; (3) Bird failed to disclose that its internal controls were not effective as they relate to calculating Sharing Revenue recognition; (4) as a result, Bird would need to restate its previously disclosed Sharing Revenue; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC





View source version on accesswire.com:

https://www.accesswire.com/729033/CURV-OLPX-BRDS-Class-Action-Reminders-Bronstein-Gewirtz-Grossman-LLC-A-Top-Firm-Reminds-Investors-of-Deadlines-and-to-Actively-Participate



comtex tracking

COMTEX_422552393/2457/2023-01-12T11:01:25

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.